Erika Hamilton shared a post by Giuseppe Curigliano, Chief of the Clinical Division of Early Drug Development at European Institute of Oncology, Milan, Italy, on X, adding the following:

“Really feel like we don’t need to be testing for HER-2 for TDXd in breast cancer:
1) IHC testing isn’t that good
2) HER-2 is so heterogeneous biopsy to biopsy
3) other ADCs we don’t test (TROP, HER-3 etc). Only b/c it was “HER-2″ did we get stuck in this testing algorithm to begin with!”

Quoting Giuseppe Curigliano’s post:

“ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial -”

Source: Erika Hamilton/X and Giuseppe Curigliano/X

Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective.

Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee a ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee.

She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.
OncoDaily